ERBB2 and breast carcinoma: Impassion050 did not detect pCR improvement (ITT population: 62.4% vs. 62.7%; PD-L1+ cohort: 64.2% vs. 72.5%) in patients with high-risk (defined as >2 cm in size, node+) HER2+ breast cancer who received neoadjuvant dose-dense anthracycline, taxane, trastuzumab, and pertuzumab with or without atezolizumab [55].